Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multiple Sclerosis Drug Prices Rising By Double-Digits Despite Rebates

Executive Summary

Report by the Massachusetts Attorney General’s office offers a unique view of net price trends because it is based on point-of-sale spending and hard-to-get rebate data.

You may also be interested in...



Woodcock Becomes PCORI Board's First FDA Representative

Center for Drug Evaluation and Research director accepts six-year term on Board of Governors of the Patient-Centered Outcomes Research Institute, which funds comparative effectiveness studies.

MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts – ICER Report

List pricing for Biogen’s Tecfidera and Novartis’ Gilenya would need to be discounted 47% and 50%, respectively, for them to be considered good values, ICER concludes in a new report. But three products come in under ICER's thresholds.

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.

Topics

Related Companies

UsernamePublicRestriction

Register

PS119328

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel